Farnesyltransferase inhibitors: A promising future in cancer treatment

Clinical Lung Cancer

Volumn 4, Issue 1, 2002, Pages 63-64

  Khuri, Fadlo R ^a   Cohen, Victor ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANGIOGENESIS INHIBITOR; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; L 778123; LONAFARNIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TIPIFARNIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYPOTHESIS; LUNG NON SMALL CELL CANCER; ONCOGENE RAS; SIGNAL TRANSDUCTION;

EID: 0036638085     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70674-X     Document Type: Note

References (13)

1. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
2. Blocking oncogenic Ras signaling for cancer therapy
3. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies
4. Phase I trial of the farnesyl protein transferase inhibitor L-778,123 on a 14 or 28-day schedule
5. Evolving therapies: Farnesyltransferase inhibitors
6. The role of farnesyltransferase inhibitors in lung cancer therapy
7. A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small-cell lung cancer
8. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines
9. A phase I trial of the farnesyltransferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
10. Induction therapy with SCH66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck
11. Phase I study of farnesyltransferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
12. A phase I/II study of farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) with paclitaxel in taxane-refractory/resistant patients with non-small cell lung cancer (NSCLC): Final report
13. Lung cancer chemoprevention: Current status and future directions